Item Type | Name |
Concept
|
Cisplatin
|
Academic Article
|
Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.
|
Academic Article
|
Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.
|
Academic Article
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
Academic Article
|
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
|
Academic Article
|
Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
|
Academic Article
|
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach.
|
Academic Article
|
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
|
Academic Article
|
Multimodality therapy in advanced paranasal sinus carcinoma: superior long-term results.
|
Academic Article
|
Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.
|
Academic Article
|
Concomitant chemoradiotherapy with cisplatin, 5-fluorouracil and hydroxyurea in poor-prognosis head and neck cancer.
|
Academic Article
|
Xrcc3 is required for assembly of Rad51 complexes in vivo.
|
Academic Article
|
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer.
|
Academic Article
|
Radioresistant derivatives of radiosensitive CHO cells obtained following treatment with 5-azacytidine retain their sensitivity to cisplatin.
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
Academic Article
|
Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage.
|
Academic Article
|
cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway.
|
Academic Article
|
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin.
|
Academic Article
|
Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis.
|
Academic Article
|
Transcriptional control of viral gene therapy by cisplatin.
|
Academic Article
|
Curative radiotherapy following chemotherapy for invasive bladder carcinoma (a preliminary report).
|
Academic Article
|
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer.
|
Academic Article
|
Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.
|
Academic Article
|
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.
|
Academic Article
|
A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin.
|
Academic Article
|
Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study.
|
Academic Article
|
An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck.
|
Academic Article
|
A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer.
|
Academic Article
|
Platinum complexes inhibit repair of potentially lethal damage following bleomycin treatment.
|
Academic Article
|
A chemical compound that stimulates the human homologous recombination protein RAD51.
|
Academic Article
|
Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer.
|
Academic Article
|
Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck.
|
Academic Article
|
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
Academic Article
|
Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate-leucovorin chemotherapy.
|
Academic Article
|
Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer.
|
Academic Article
|
Treatment of advanced squamous cell carcinoma of the head and neck with cisplatin, bleomycin, and methotrexate (PBM).
|
Academic Article
|
X-ray and cis-diamminedichloroplatinum(II) cross-resistance in human tumor cell lines.
|
Academic Article
|
Toxicity of aggressive multimodality therapy including cisplatinum, bleomycin and methotrexate with radiation and/or surgery for advanced head and neck cancer.
|
Academic Article
|
The role of paclitaxel in the treatment of head and neck cancer.
|
Academic Article
|
Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents.
|
Academic Article
|
Advanced squamous carcinoma of the head and neck. A preliminary report of neoadjuvant chemotherapy with cisplatin, bleomycin, and methotrexate.
|
Academic Article
|
Chemotherapy for advanced carcinoma of the head and neck. A clinical update.
|
Academic Article
|
Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience.
|
Academic Article
|
Activation of p38 mitogen-activated protein kinase by c-Abl-dependent and -independent mechanisms.
|
Academic Article
|
Measurement of bioreduction rates of cells with distinct responses to ionizing radiation and cisplatin.
|
Academic Article
|
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer.
|
Academic Article
|
Radioresistant derivatives of an X-ray-sensitive CHO cell line exhibit distinct patterns of sensitivity to DNA-damaging agents.
|
Academic Article
|
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer.
|
Academic Article
|
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer.
|
Academic Article
|
Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
|
Academic Article
|
Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer.
|
Academic Article
|
Locoregionally advanced paranasal sinus carcinoma. Favorable survival with multimodality therapy.
|
Academic Article
|
Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
|